FDA Approves Olezarsen to Reduce Triglycerides and Acute Pancreatitis Risk in Severe Hypertriglyceridemia

The U.S. Food and Drug Administration (FDA) has approved olezarsen as the first treatment shown to reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia. Olezarsen was previously approved in December 2024 as an adjunct to diet for familial chylomicronemia syndrome (FCS), a rare genetic form of severe hypertriglyceridemia.